Postpartum Depression Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Postpartum Depression Treatment Market
The Postpartum Depression Treatment market size was valued at USD 12.2 million in 2023, and the market is now projected to grow from USD 79.9 million in 2024 to USD 973.0 million by 2032, exhibiting a CAGR of 36.7% during the forecast period of 2024-2032.
The reason behind the slowed down in market growth is that many people do not go for treatment when they give birth because of fear they might be infected with COVID-19. Moreover, the Postpartum Depression Treatment market growth could not be expanded during the pandemic since there were also other factors like lack of diagnosis facilities. Apart from these reasons, there were also some other reasons why there was no growth of the market during this period of time even after approval on postnatal depression medications.
Some HTML & CSS are written in a way that you have to follow certain procedures so that the code can work. This Postpartum Depression Treatment market share adherence to a specific perception of how the language should behave in different contexts means the language has conventions that require certain steps or decisions be made.
Specific patient care tools are increasingly needed as cases of postpartum depression are on the rise. There are now various technologies such as gadgets and techniques which adopt AI and ML technology for better understanding the symptoms as well as treatment options hence management can be enhanced.
Comprehensive Analysis of Postpartum Depression Treatment Market
The Postpartum Depression Treatment market and Healthcare industry Grows rapidly because of the way it is broken down into smaller markets. These segmentations are methodically segregated by Drug Analysis, by Route of Administration Analysis, by Distribution Channel Analysis. The Drug Analysis, brexanolone, zuranolone, and others. However, the Route of Administration Analysis, parenteral, oral, and others. The Distribution Channel Analysis, specialty pharmacies and hospital pharmacies.
The North American region was in charge for making the largest market of the Postpartum Depression Treatment sale of USD 12.2 million in 2023 due to It is expected that the region will be one of the best regions in the market.
The top players in the market play a crucial role in the Healthcare industry prospectus growth and setting market standards. These players include, Biogen Inc. (U.S.), Sage Therapeutics, Inc. (U.S.), GH Research Ireland Limited (Ireland), Brii Biosciences Limited (China), these market players provide a level-playing competitive landscape.
In August 2023, Sage Therapeutics, Inc. and Biogen Inc. have jointly announced the United States Food and Drug Administration’s approval of ZURZUVAE (zuranolone)—the inaugural orally prescribed medication that can immediately alleviate the depression in postpartum women. That judgment serves as a substantial breakthrough when it comes to medical care for PPD by giving swift respite through an easily accessible mode of therapy.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 36.7% from 2024-2032
Unit Value (USD million)
Segmentation ByDrug
Zuranolone
Brexanolone
Others
ByRoute of Administration
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
By Region
North America (By Drug, Route of Administration, Distribution Channel, and Country/Sub-Region)
- U.S.
- Canada
Asia Pacific (By Drug, Route of Administration, Distribution Channel, and Country/Sub-Region)
- China
- Japan
- India
- Australia
- Rest of the Asia Pacific
Rest of the World ( By Drug, Route of Administration, and Distribution Channel)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.